MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases

Two cancer testis antigens, the New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and the melanoma-antigen family A (MAGE-A), represent promising immunotherapy targets due to the low expression of these antigens in nonmalignant tissue. To assess overexpression patterns in various cancers, we performed a systematic immunohistochemical analysis for NY-ESO-1 and MAGE-A on tissue array samples of 3668 common epithelial carcinomas (CA) and germ cell tumors of high prevalence and mortality. Here, we find significantly higher expression of MAGE-A (>50% on tumor cells) compared with NY-ESO-1 in several CAs including cutaneous squamous cell carcinomas (SCC) (52.8%/2.8%), esophageal SCC (50%/0%), head and neck SCC (41.1%/<1%), bladder urothelial CA (40.4%/8.3%), cervical/anal SCC (37.5%/0%), lung SCC (34%/3.8%), lung adenocarcinomas (27.6%/3.9%), ovarian CA (26.4%/3.6%), endometrial CA (26.3%/1.3%), lung small cell CA (24.4%/2.4%), gastric adenocarcinomas (20%/4%), breast mucinous CA (19.3%/0%), hepatocellular CA (18.8%/1.2%), breast infiltrating ductal CA (16.4%/1.8%), colorectal adenocarcinomas (10.7%/<1%), cholangiocarcinomas (9.8%/0%), thymic CA (9%/4.5%), and mesotheliomas (7.9%/<1%). Furthermore, high expression of MAGE-A, but not NY-ESO-1, was seen in whole slide evaluations of an independent cohort of metastatic SCC (45.5%/3.6%) and metastatic CA (13.5%/0%) of various primaries with significantly higher expression of MAGE-A in metastatic SCC compared with other metastatic CA. MAGE-A is also more highly expressed in germ cell tumors, seminomas (69%/3.5%) and nonseminomas (40.1%/4.7%). In summary, MAGE-A is more highly expressed than NY-ESO-1 in a majority of human malignancies, and targeting MAGE-A may benefit a large number of patients.

[1]  Yao-Tseng Chen,et al.  NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. , 2003, Cancer research.

[2]  Loise M. Francisco,et al.  The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells , 2015, Journal of Immunotherapy for Cancer.

[3]  D. Xie,et al.  [Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma]. , 2005, Ai zheng = Aizheng = Chinese journal of cancer.

[4]  Snehal G. Patel,et al.  Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck , 2004, Head & neck.

[5]  T. Kidokoro,et al.  Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer , 2015, Clinical Cancer Research.

[6]  Thierry Boon,et al.  Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.

[7]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[8]  L. Terracciano,et al.  NY‐ESO‐1/LAGE‐1 coexpression with MAGE‐A cancer/testis antigens: A tissue microarray study , 2005, International journal of cancer.

[9]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[10]  M. Raffeld,et al.  MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma , 2009, Clinical Cancer Research.

[11]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[12]  M. Miettinen.  A Simple Method for Generating Multitissue Blocks Without Special Equipment , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[13]  V. Reuter,et al.  Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. , 2003, Cancer immunity.

[14]  Yao-Tseng Chen,et al.  NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. , 2003, Cancer immunity.

[15]  K. Hatakeyama,et al.  NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer , 2004, Cancer Chemotherapy and Pharmacology.

[16]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[17]  M. Raffeld,et al.  NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis , 2012, Modern Pathology.

[18]  M. Sang,et al.  MAGE-A family: attractive targets for cancer immunotherapy. , 2011, Vaccine.

[19]  L. Lacombe,et al.  High frequency of MAGE‐A4 and MAGE‐A9 expression in high‐risk bladder cancer , 2009, International journal of cancer.

[20]  M. Atkins,et al.  Prognostic and predictive markers for the new immunotherapies. , 2014, Oncology.

[21]  Sadik H. Kassim,et al.  A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.

[22]  E. Smeland,et al.  NY‐ESO‐1 protein expression and humoral immune responses in prostate cancer , 2004, The Prostate.

[23]  Phyu P Aung,et al.  Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. , 2014, Human pathology.

[24]  A. Simpson,et al.  The cancer/testis genes: review, standardization, and commentary. , 2004, Cancer immunity.

[25]  Yao-Tseng Chen,et al.  Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. , 2001, Cancer research.

[26]  N. Altorki,et al.  Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues , 2001, International journal of cancer.

[27]  N. Restifo,et al.  Cellular constituents of immune escape within the tumor microenvironment. , 2012, Cancer research.